Sanofi (NASDAQ:SNY) Announces Earnings Results

Sanofi (NASDAQ:SNY) announced its earnings results on Thursday. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.05, Zacks reports. The firm had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a return on equity of 38.98% and a net margin of 9.60%. The business’s revenue was up 7.8% compared to the same quarter last year. During the same period last year, the firm posted $0.95 EPS.

Sanofi Stock Performance

SNY traded down $0.70 on Friday, hitting $52.40. The company’s stock had a trading volume of 1,994,568 shares, compared to its average volume of 2,357,098. Sanofi has a 12 month low of $42.63 and a 12 month high of $55.72. The firm has a market cap of $132.72 billion, a P/E ratio of 26.33, a price-to-earnings-growth ratio of 1.63 and a beta of 0.59. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The company’s 50 day simple moving average is $49.21 and its 200-day simple moving average is $48.69.

Analyst Upgrades and Downgrades

Several analysts have commented on SNY shares. StockNews.com raised shares of Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Friday. Argus lifted their price target on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.